Pharmafile Logo

Wilmington Healthcare appoints new Solutions Director

May 27, 2021 | NHS, Promotion, healthcare 

Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare

Wilmington Healthcare, a market leader in the provision of data, insight and intelligence for pharma and medtech companies, has announced the promotion of Kirsty Fryer to the role of Solutions Director.

In her new role, Kirsty will be responsible for the Quantis portfolio of products offered by Wilmington Healthcare, leading the team as they continue to deliver outstanding service and solutions to the organisation’s customers. Bringing together all disciplines, from analytical, development, commercial and marketing to underpin Wilmington Healthcare’s ambitious growth plans, Kirsty will ensure customers continue to receive trusted insight and real-world data solutions.

Kirsty steps up to the role having been Solutions Consultant since November 2017 and a valued member of the Wilmington Healthcare team since 2015. In this time, she has developed her career from bespoke researcher supporting the organisation’s understanding of the healthcare ecosystem before joining the solutions team working with real-world evidence – transforming data-led insight into core messages and potential implications. With a PhD in Neurophysiology from the University of Nottingham and currently undertaking an MBA with senior leadership focus she brings a wealth of expertise to the role alongside her existing client relationships.

Welcoming the appointment Jonathan Carney, of Wilmington Healthcare, says: “Kirsty has been a huge asset to Wilmington Healthcare since she joined the company in 2015. Her promotion to lead one of our key growth products in the role of Solutions Director is recognition for her passion, energy and commitment in delivering the very best for our customers combined with her extensive knowledge of our products and the impact they help to make in shaping sustainable commercial and partnership strategies for our customers. Through Kirsty’s appointment we will be building upon our market credentials as a trusted, leading organisation in the Healthcare Insight arena.”

Kirsty Fryer adds: ‘I’m proud of my work over the last five years within Wilmington Healthcare and I’m excited to guide our fantastic team as we continue to provide bespoke, real-world insight to meet the individual needs of our customers in parallel with the evolving needs of the NHS in this new era of healthcare impacted by the COVID-19 pandemic.”

This content was provided by Wilmington Healthcare

Company Details

 Latest Content from  Wilmington Healthcare 

How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma

New report shows Traumatic Brain Injury (TBI) is a major threat to older people

A report by healthcare intelligence provider Wilmington Healthcare and the charity, United Kingdom Acquired Brain Injury Forum (UKABIF), shows that many hospital admissions in England for Traumatic Brain Injury (TBI)...

How will Sustainability and Transformation Plans (STPs) change the NHS in 2017?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the impact that STPs will have on the NHS and what this means for pharma.

How can pharma help the NHS drive much-needed change in mental health services?

Laurence Mascarenhas, of Wilmington Healthcare, assesses how pharma can help the NHS to achieve Parity of Esteem (PoE) in mental health

How can the NHS deliver integrated care?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain the changes needed to help the NHS provide a more holistic, joined up experience for patients

How can pharma engage with NHS Vanguards?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore the opportunities for pharma to help NHS vanguards develop new models of care.

What does the Five Year Forward View mean for pharma?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.